Skip to main content
TipRanks
Go Ultimate75% OFF

Grace Therapeutics (GRCE) Stock Price & Analysis

1,209 Followers

GRCE Stock Chart & Stats

$1.81$0.00(0.00%)
At close: 4:00 PM EST
$1.75$2$2.25Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.81 - $1.83
52-Week Range
$1.67 - $5.18
Previous Close
$1.81
Volume
N/A
Average Volume (3M)
103.54K
Market Cap
$38.08M
Enterprise Value
$21.94M
Total Cash (Recent Filing)
$21.31M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
1.20
Next Earnings
Feb 15, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

An essentially debt-free balance sheet reduces interest obligations and refinancing exposure while preserving flexibility to fund development. This is a durable financial advantage for a development-stage company, although it does not by itself resolve the need to finance ongoing operations.

Proprietary Delivery Platform

A proprietary topical and transdermal platform gives Grace a defined product-development strategy rather than a broad, unfocused research model. If successfully commercialized, improved localized delivery and patient experience could support differentiated pharmaceutical products in dermatology and related areas.

Governance Continuity

Shareholder support for the board, executive compensation and auditor reinforces continuity in oversight and financial reporting. The annual advisory vote on pay also preserves an ongoing mechanism for investor input, supporting stable governance while the company advances its development strategy.

Bears Say

No Revenue And Persistent Losses

No reported revenue and a substantial continuing net loss indicate that the business has not yet reached commercial scale or demonstrated operating profitability. This limits internal funding capacity and leaves future financial performance dependent on successful product development and eventual commercialization.

Ongoing Cash Burn

Persistently negative operating and free cash flow show that current activities consume cash rather than fund themselves. Continued development spending therefore likely requires external financing over time, which can constrain strategic flexibility and expose the company to dilution or financing availability risk.

Shrinking Equity Base

The sharp reduction in equity alongside materially negative returns indicates that accumulated losses are eroding the capital base. Even with minimal debt, continued deterioration could reduce financial resilience and leave fewer internally funded resources available for advancing the company’s pipeline.

Grace Therapeutics News

GRCE FAQ

What was Grace Therapeutics’s price range in the past 12 months?
Grace Therapeutics lowest stock price was $1.67 and its highest was $5.18 in the past 12 months.
What is Grace Therapeutics’s market cap?
Grace Therapeutics’s market cap is $38.08M.
When is Grace Therapeutics’s upcoming earnings report date?
Grace Therapeutics’s next earnings report is estimated for Feb 15, 2027 (not yet confirmed), which is in 91 days.
How were Grace Therapeutics’s earnings last quarter?
Grace Therapeutics released its earnings results on Nov 12, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.04.
Is Grace Therapeutics overvalued?
According to Wall Street analysts Grace Therapeutics’s price is currently Undervalued.
Does Grace Therapeutics pay dividends?
Grace Therapeutics does not currently pay dividends.
What is Grace Therapeutics’s EPS estimate?
Grace Therapeutics’s EPS estimate is -0.15.
How many shares outstanding does Grace Therapeutics have?
Grace Therapeutics has 21,035,930 shares outstanding.
What happened to Grace Therapeutics’s price movement after its last earnings report?
Grace Therapeutics reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went down -2.426%.
Which hedge fund is a major shareholder of Grace Therapeutics?
Currently, no hedge funds are holding shares in GRCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology